Although the present study provides meaningful contributions regarding potential markers for extended olaparib therapy, more comprehensive studies are essential to improve our understanding of PARP inhibitors and refine therapeutic approaches to ovarian cancer. The gene discussed is PARP1; the disease is ovarian cancer.